@article{discovery10064190,
           title = {A novel ELISA for the measurement of cerebrospinal fluid SNAP-25 in patients with Alzheimer's disease},
            note = {{\copyright} 2018 The Authors.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).},
            year = {2018},
         journal = {Neuroscience},
        abstract = {Synaptic degeneration is central in Alzheimer's disease (AD) pathogenesis and biomarkers to monitor this pathophysiology in living patients are warranted. We developed a novel sandwich enzyme-linked immunosorbent assay (ELISA) for the measurement of the pre-synaptic protein SNAP-25 in cerebrospinal fluid (CSF) and evaluated it as a biomarker for AD. CSF samples included a pilot study consisting of AD (N=26) and controls (N=26), and two independent clinical cohorts of AD patients and controls. Cohort I included CSF samples from patients with dementia due to AD (N=17), patients with mild cognitive impairment (MCI) due to AD (N=5) and controls (N=17), and cohort II CSF samples from patients with dementia due to AD (N=24), patients with MCI due to AD (N=18) and controls (N=36). CSF levels of SNAP-25 were significantly increased in patients with AD compared with controls (P{$\leq$}0.00001). In both clinical cohorts, CSF levels of SNAP-25 were significantly increased in patients with MCI due to AD (P{\ensuremath{<}}0.0001). SNAP-25 could differentiate dementia due to AD (N=41) from controls (N=52) and MCI due to AD (N=23) from controls (N=52) with areas under the curve of 0.967 (P{\ensuremath{<}}0.0001) and 0.948 (P{\ensuremath{<}}0.0001), respectively. CSF SNAP-25 is a promising AD biomarker that differentiates AD patients in different clinical stages of the disease from controls with excellent diagnostic accuracy. Future studies should address the specificity of the CSF SNAP-25 against common differential diagnoses to AD, as well as how the biomarker changes in response to treatment with disease-modifying drug candidates.},
        keywords = {Alzheimer's disease, Biomarker, Cerebrospinal fluid, ELISA, Mild cognitive impairment, SNAP-25},
            issn = {1873-7544},
             url = {https://doi.org/10.1016/j.neuroscience.2018.11.038},
          author = {{\"O}hrfelt, A and Brinkmalm, A and Dumurgier, J and Zetterberg, H and Bouaziz-Amar, E and Hugon, J and Paquet, C and Blennow, K}
}